Cover Image

Patient‐Centric Pragmatic Clinical Trials: Opening the DOOR

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Scott R. Evans, Qihang Wu, Toshimitsu Hamasaki
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Statistics in Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

On Cluster Randomized Trials with the Desirability of Outcome Ranking (DOOR) Endpoints
by: Shao, Wanying, et al.
Published: (2026)

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
by: Yuwei Cheng, et al.
Published: (2026)

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation
by: Chloe E. Falke, et al.
Published: (2025)

Desirability of outcome ranking (DOOR) analysis for multivariate survival outcomes with application to ACTT-1 trial
by: Shu, Shiyu, et al.
Published: (2025)

Futility Monitoring in Clinical Trials
by: Ana M. Ortega‐Villa, et al.
Published: (2025)

An Empirical Assessment of the Cost of Dichotomization of the Outcome of Clinical Trials
by: Erik W. van Zwet, et al.
Published: (2026)

Testing for Similarity of Dose Response in Multiregional Clinical Trials
by: Holger Dette, et al.
Published: (2025)

RMST for Interval‐Censored Data in Oncology Clinical Trials
by: Xiyuan Gao, et al.
Published: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
by: Gi‐Ming Wang, et al.
Published: (2026)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
by: Alessandra Serra, et al.
Published: (2025)

Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints
by: Jingya Gao, et al.
Published: (2024)

On Anticipation Effect in Stepped Wedge Cluster Randomized Trials
by: Hao Wang, et al.
Published: (2026)

Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles
by: Kim May Lee, et al.
Published: (2026)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
by: Yuan Li, et al.
Published: (2025)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
by: Adrien Ollier, et al.
Published: (2025)

A Saddlepoint Framework for Accurate Inference in Multicenter Clinical Trials With Imbalanced Clusters
by: Haidy A. Newer
Published: (2026)

Sequential Monitoring of Covariate‐Adaptive Randomized Clinical Trials With Non‐Parametric Approaches
by: Xiaotian Chen, et al.
Published: (2025)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
by: Moka Komaki, et al.
Published: (2026)

Time‐Varying Treatment Effect Models in Stepped‐Wedge Cluster‐Randomized Trials With Multiple Interventions
by: Zhe Chen, et al.
Published: (2026)

Dynamic Borrowing From Historical Controls via the Synthetic Prior With Covariates in Randomized Clinical Trials
by: Daniel E. Schwartz, et al.
Published: (2026)

Synergy Area With FDR ‐Controlled Evaluation ( SAFE ) to Robustly Assess Safety Profile in Clinical Trials
by: Tianyu Zhan, et al.
Published: (2026)

Matching‐Assisted Power Prior for Incorporating Real‐World Data in Randomized Clinical Trial Analysis
by: Ruoyuan Qian, et al.
Published: (2025)

Doubly Robust Estimation and Sensitivity Analysis With Outcomes Truncated by Death in Multi‐Arm Clinical Trials
by: Jiaqi Tong, et al.
Published: (2025)

The Cox Model With Adaptive Fused Group Bridge Penalty to Incorporate Historical Data Into the Analysis of Clinical Trials With an Application to BMT CTN 1101
by: Xi Fang, et al.
Published: (2025)

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
by: Hyejung Jung, et al.
Published: (2026)

Balancing Events, Not Patients, Maximizes Power of the Logrank Test: And Other Insights on Unequal Randomization in Survival Trials
by: Godwin Yung, et al.
Published: (2025)

Sample Size Adjustment in Sequential Multiple Assignment Randomized Trials
by: Liwen Wu, et al.
Published: (2025)

Natural Effects in the Presence of an Intermediate Confounder: Evaluation of Pragmatic Estimation Strategies With an Emphasis on the Relationship Between Natural and Interventional Effects
by: Jesse Gervais, et al.
Published: (2025)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
by: Xinran Huang, et al.
Published: (2024)

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo
by: Fei Gao, et al.
Published: (2025)

Unlocking Cognitive Analysis Potential in Alzheimer's Disease Clinical Trials: Investigating Hierarchical Linear Models for Analyzing Novel Measurement Burst Design Data
by: Guoqiao Wang, et al.
Published: (2024)

Comments on “Novel Non‐Linear Models for Clinical Trial Analysis With Longitudinal Data: A Tutorial Using SAS for Both Frequentist and Bayesian Methods”
by: M. C. Donohue, et al.
Published: (2025)

A Partially Randomized Patient Preference, Sequential, Multiple‐Assignment, Randomized Trial Design Analyzed via Weighted and Replicated Frequentist and Bayesian Methods
by: Marianthie Wank, et al.
Published: (2024)

Response to Letter to the Editor “Comments on ‘Novel Non‐Linear Models for Clinical Trial Analysis With Longitudinal Data: A Tutorial Using SAS for Both Frequentist and Bayesian Methods’”
by: Guoqiao Wang, et al.
Published: (2025)

Probabilistic Clustering Using Multivariate Growth Mixture Model in Clinical Settings—A Scleroderma Example
by: Ji Soo Kim, et al.
Published: (2026)

The Design of Large‐Scale Plasma Donation Trials
by: Kecheng Li, et al.
Published: (2025)

Model‐Robust Standardization in Cluster‐Randomized Trials
by: Fan Li, et al.
Published: (2025)

Bayesian Random‐Effects Meta‐Analysis of Aggregate Data on Clinical Events
by: Christian Röver, et al.
Published: (2026)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I– II Oncology Dose Finding Trials
by: Andrew Hall, et al.
Published: (2026)

Correction to “Model‐Robust Standardization in Cluster‐Randomized Trials”
Published: (2026)